The involvement of Notch signaling in melanoma vasculogenic mimicry

Clinical and Experimental Medicine

Volumn 13, Issue 3, 2013, Pages 201-209

  Vartanian, Amalia ^a   Gatsina, Galina ^a   Grigorieva, Irina ^a   Solomko, Elico ^a   Dombrovsky, Vladislav ^a   Baryshnikov, Anatoly ^a   Stepanova, Eugenia ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Melanoma; Notch signaling; Vasculogenic mimicry

Indexed keywords

DIBENZAZEPINE DERIVATIVE; GAMMA SECRETASE INHIBITOR; GELATINASE A; JAGGED1 NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; NOTCH RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; MELANOMA CELL; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84881477196     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-012-0190-9     Document Type: Article

References (32)

1. Feige JJ (2010) Tumour angiogenesis: recent progress and remaining challenges. Bull Cancer 97(11):1305-1310
2. Hiratsuka S (2011) Vasculogenesis, angiogenesis and special features of tumour blood vessels. Front Biosci 16:803-814
3. Quesada AR, Medina MA, Munoz-Chapuli R, Ronce AL (2010) Do not say ever never more: the ins and outs of antiangiogenic therapies. Curr Pharm Des 16(35):3932-3957
4. Sharma PS, Sharma R, Tyagi T (2011) VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and Future. Curr Cancer Drug Targets 11(5):624-633
5. Gerger A, LaBonte M, Lenz HL (2011) Molecular predictors of response to antiangiogenesis therapies. Cancer J 17(2):134-141
6. Fan YZ, Sun W (2010) Molecular regulation of vasculogenic mimicry in tumours and potential tumor-target therapy. World J Gastrointest Surg 2(4):117-124
7. Paulis YW, Soetekouw PM, Verheul HM (2010) Signaling pathways in vasculogenic mimicry. Biochem Biophys Acta 1806(1):18-28
8. Schwanbeck R, Martini S, Bernoth K, Just U (2011) The Notch signalling pathway: molecular basis of cell content dependency. Eur J Cell Biol 90(6-7):572-581
9. Eiken HM, Adams RM (2010) Dynamics of endothelial cell behaviour in sprouting angiogenesis. Curr Opin Cell Biol 22(5):617-625
10. Koch U, Radtke F (2010) Notch signaling in solid tumor. Curr Top Dev Biol 92:367-409
11. Guo S, Liu M, Gouzalez-Perez RR (2011) Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochem Biophys Acta 1815(2):197-213
12. Aster JC, Blacklow SC, Pear WS (2011) Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223(2):262-273
13. Sjolund J, Johanson M, Manna S, Norin C, Pietras A, Beckman S, et al. (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signalling in vitro and in vivo. J Clin Invest 118(1):217-228
14. Massi D, Tarantini F, Franchi A, Paglierani M, Serio Di, Pellerito S, et al. (2006) Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Modern Pathol 19:246-254
15. Jabobsson L, Bentley K, Gerhardt U (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 37(6):216-233
16. Cristofaro B, Emanueli C (2009) Possible novel targets for theraupetic angiogenesis. Curr Opin Pharmacol 9(2):102-108
17. Mikhailova IN, Lukashina MI, Baryshnikov AYu, Morozova LF, Kiselev CL, Georgiev GP (2005) Melanoma cell lines as the basis for antitumor vaccine preparation. Vest Ross Akad Med Nauk 7:37-40
18. Mikhailova IN, Kovalevsky DA, Morozova LF, Burova OS, Baryshnikov AYu, Bibilashvili RS (2008) Cancer/testis genes expression in human melanoma cell lines. Mel Res 18(5):303-313
19. Vartanian A, Burova O, Stepanova E, Baryshnikov AYu, Lichinitser MR (2007) The involvement of apoptosis in melanoma vasculogenic mimicry. Mel Res 17:1-8
20. Gridley T (2010) Notch signalling in the vasculature. Curr Top Dev Biol 92:277-309
21. Liu Z, Xiao M, Balint K, Smally K, Bradford P, Qiu R, et al. (2006) Notch signalling promotes primary melanoma progression by activating Mitogen-activated protein kinase/phosphatidylinosotol 3-kinase-Akt pathway and upregulate N-cadherin expression. Cancer Res 66:4182-4190
22. Kame T (2009) Novel insights into the differentiatial funcrions of Notch ligands in vascular formation. J Angiogeneisi Res 16:1-8
23. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. (2009) Preclinical profile of a potent γ-secretase inhibitor targeting Notch signalling with in vivo efficacy and pharmacodynamic properties. Cancer Res 68(19):7672-7680
24. Hess AR, Seftor EA, Seftor RE, Hendrix MJ (2003) Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757-4762
25. Vartanian A, Stepanova E, Grigorieva I, Solomko E, Baryshnikov A, Lichinitser M (2011) VEGFR1 and PKCalpha signalling control melanoma vasculogenic mimicry in a VEGFR2 kinase-independent manner. Mel Res 21(2):91-98
26. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J (2011) VEGFR1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 71(4):1474-1485
27. Helfrich E, Schadendorf D (2011) Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic resistance? Mol Oncol 5:137-149
28. Ko JM, Verez NF (2010) Tsao H Pathways to melanoma. Semin Cutan Med Surg 29(4):210-217
29. Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. Apmis 112:508-525
30. Yan M, Plowman GB (2007) Delta-like 4/Notch signalling and its theraupetic implications. Cancer Res 13(24):7243-7246
31. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Hendrix MJ (2010) Regulation of the embryonic morphogen Nodal by Notch facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70(24):1034010350
32. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231